Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa^® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE). There are an estimated 900,000 DVT and PE events per year in the U.S., approximately one-third of which result in death from PE.

"Venous thromboembolism is the third most common cardiovascular disease after myocardial infarction and stroke. About one-third of patients with a DVT or PE will suffer a recurrence within 10 years," said Samuel Z. Goldhaber, M.D., Director of Brigham and Women's Hospital's Thrombosis Research Group and Professor of Medicine, Harvard Medical School. "Dabigatran has established efficacy and safety for stroke risk reduction in patients with non-valvular atrial fibrillation. This new FDA approval expands dabigatran's indications to include treatment and the reduction of the risk of recurrence of DVT and PE."

The approval is based on results from four global Phase III studies evaluating the efficacy and safety of PRADAXA in the treatment of DVT and PE.

The RE-COVER^® and RE-COVER II^® trials, which included patients with DVT and PE who were treated with parenteral anticoagulant therapy for five to 10 days, showed PRADAXA was non-inferior to warfarin in reducing DVT and PE after a median of 174 days of treatment, and was associated with lower rates of overall bleeding and a higher rate of any gastrointestinal (GI) bleeding (3.1 percent vs. 2.4 percent). RE-MEDY^SM, which included patients who had been previously treated for an acute DVT and PE with anticoagulant therapy for three to 12 months, showed PRADAXA was non-inferior to warfarin in reducing DVT and PE after a median of 534 days of treatment, and was associated with lower rates of overall bleeding and a higher rate of any GI bleeding (3.1 percent vs. 2.2 percent).

RE-SONATE^®, which included patients who had been previously treated for an acute DVT and PE with anticoagulant therapy for six to 18 months, showed PRADAXA reduced the risk of DVT and PE recurrence by 92 percent compared to placebo after a median of 182 days of treatment: 0.4 percent vs. 5.6 percent; HR = 0.08 [CI 0.02, 0.25]. PRADAXA was associated with higher rates of any bleeding (10.5 percent vs. 6.1 percent; HR = 1.77 [CI 1.20, 2.61]), clinically relevant non-major bleeding (5.0 percent vs. 2.0 percent; HR = 2.54 [CI 1.34, 4.82]), and GI bleeding (0.7 percent vs. 0.3 percent) compared to placebo.

A DVT occurs when a blood clot blocks the normal flow of blood through a vein, usually in the leg or pelvis, which may lead to swelling or pain in the affected leg. A PE occurs when a DVT, or part of it, breaks off and travels through the bloodstream to the lungs, blocking a vessel. The symptoms of a PE include shortness of breath and chest pain. It may also cause other symptoms like cough, rapid heart rate and dizziness. A PE can be life-threatening and requires urgent treatment.The standard of care for patients with a DVT or PE has been acute treatment with parenteral anticoagulation therapy, such as low-molecular-weight heparin [LMWH]), followed by long-term treatment with an oral vitamin K antagonist (e.g., warfarin).

"Deep vein thrombosis and pulmonary embolism can be life-threatening. Boehringer Ingelheim is pleased that patients will now have a new and efficacious therapeutic option for this complex condition," said Sabine Luik, M.D., senior vice president, Medicine & Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "This approval is a testament to our commitment to evaluate PRADAXA in new areas of cardiovascular treatment, in order to address evolving patient needs."

Current Experience with PRADAXA 
PRADAXA is also approved to reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF), and eight million prescriptions for PRADAXA 150 mg and 75 mg have been filled for more than 850,000 NVAF patients in the U.S. since its approval in October of 2010.

PRADAXA 150mg twice daily is the only medication among the new generation of OACs to demonstrate superior reduction of ischemic stroke compared to warfarin in patients with NVAF. PRADAXA also demonstrated a similar rate of major bleeding events.

The efficacy and safety of PRADAXA in NVAF were established in the RE-LY^® trial, one of the largest stroke prevention clinical studies ever conducted with NVAF patients. The 18,113-patient RE-LY trial showed that, compared to well-controlled warfarin>

Through the PradaxaLink™ program, patients, caregivers and healthcare providers can access a variety of valuable resources and 24-hour support regarding PRADAXA medication.